result question manag
januari
cover
summari result
consensu ep estim like reduc around suspect
market could brace wors top-lin colgat major
issu late front beat lfl lfl guidanc
vs consensu current rather encourag
colgat comment focu premium innov improv digit
capabl becom data-driven product drive margin
maintain ep estim materi unchang
mid-term organ sale growth profil high margin littl entic howev
stock trade close post crisi low rel us hpc peer consensu forward price-to-earnings
maintain neutral rate target price
question manag
main driver behind weak price strong volum deliveri
north america
exan bnpp estim thomson reuter consensu list currenc dividend reinvest yearli averag price fy end
date time london time invest recommend finalis may differ date time broad
dissemin websit see appendix analyst certif import disclosur non-u research analyst disclosur
result question
summari result
consensu ep estim like reduc around suspect
market could brace wors top-lin
colgat major issu late front beat lfl
lfl guidanc vs consensu current
figur outlin main element releas rel
consensu expect
figur summari result rel expect
varianc
compani consensu per visibl alpha exan bnp pariba estim
colgat offer follow guidanc pointer wrt
sale growth includ recent hello product acquisit
organ sale growth
non-gaap ep growth low mid-single-digit increas
gaap ep growth mid high-single-digit increas
highlight main newsworthi item may easili glean
quick read releas
focu innov primarili premium innov faster
bring innov market improv digit becom data-driven
product drive margin scope effici suppli
coronaviru stage seem neg impact
colgat busi china least temporari colgat abl
provid colour cagni consum analyst group new york confer
total relaunch total saw fastest growth year colgat took
price increas busi quit happi price situat
hill scienc diet relaunch late europ expand
rest world hill saw double-digit growth us double-
digit growth scienc diet clearli face tougher comp
strong innov come prescript diet
hello posit complement colgat portfolio well lifestyle-typ
brand free-form type posit score high amongst millenni
 colgat brand perform
e-commerc colgat pleas e-commerc overal lfl growth
overal hill china colgat start develop strateg partnership
alibaba jd
em mexico technic face recess macro brazil recov
somewhat overal colgat categori hold well happi latin
america colgat obvious pleas asia pacif turnaround asia
take time portfolio go-to-market innov need get right
south africa good china colgat colgat darli franchis
continu perform well particularli darli came back nice colgat
saw good price volum volcan innov china
europ overal colgat optimist europ go total
well uk howev clearli categori wont grow fast europ north
america em
north america clearli focu premium innov
skin care elta pca achiev doubl digit growth colgat
activ think expans new geographi china big piec term
growth elta filorga colgat need see viru situat unfold
promot colgat competitor step promot activ
toothpast north america coupon colgat howev remain focus
strategi colgat consist strategi improv lfl
beyond premium innov colgat much focus product
product north america come
em/dm colgat categori grow around faster em dm
growth consecut quarter sequenti acceler lfl
growth highest level organ growth last year
gross margin gm price raw materi
product includ mix filorga
sale guidanc includ around filorga hello
modest neg fx
tax rate non- basi
maintain ep estim materi unchang
figur outlin revis previou ep estim
figur summari ep revis
mid-term organ sale growth profil high margin littl entic
howev stock trade post crisi low rel us hpc peer
rate target price
maintain neutral rate target price
question manag
main driver behind weak price strong volum
deliveri north america
local brand nich offer global player gsk sensodyn
see market share pressur recent
deal pressur variou geographi
colgat mention press reuter novemb
interest coti profession busi relat brand would salon hair care
categori potenti interest
term given recent track record fair assum skin
area interest
comp hill particularli tough base case
assumpt busi growth year
clearli earli dive expect would
base case assumpt term spend sale rel
back total relaunch price increas price elast
demand in-lin expect concern volum
two year gross margin contract give confid
guidanc gross margin expans
market particip may argu master-brand presenc oral care
categori necessarili advantag thought work
in-hous develop new non-colg non-tot oral care brand
market particip struggl envisag materi earn growth colgat
given alreadi high level margin would pushback
global share toothpast plateau
downward trajectori sinc believ action youv taken total
relaunch help rebuild global share
sensodyn patanjali splat saki hello gain share back
consum desir local specialis natur brand possibl
view broad global brand like total sustain market share
hello sale approxim
earli day noel wallac tenur ceo chang
level share buyback would suggest factor
pleas see overleaf revis segment sale profit loss account
sale
sale non-gaap
profit tax
profit taxat non-gaap
profit continu oper
profit continu oper non-gaap
basic number share averag
fulli dilut number share averag
pay-out ratio basic non-gaap
dividend cover basic non-gaap
depreci amortis
net profit margin minor non-gaap
invest case valuat risk
mid-term organ sale growth profil high margin littl entic
howev stock trade close post crisi low rel us hpc peer
consensu forward price-to-earnings
valu colgat ep
upsid
risk would highlight includ possibl colgat subject
downsid
risk would highlight includ possibl colgat engag
margin rebas order stimul top-lin growth
cross mikheil omanadz jeff stent heidi vesterinen author contributor report herebi certifi view express report
accur reflect person view compani compani secur discuss report part compens
directli indirectli relat specif recommend view express research report
research analyst name involv prepar research report research analyst exan sa includ exan sa branch base
unit kingdom european econom area switzerland associ person exan inc thu regist qualifi
research analyst financi industri regulatori author finra new york stock exchang nyse non-u analyst subject
nasd rule nyse rule restrict commun subject compani public appear trade secur held research analyst
